Meta-analysis of 25 studies in patients with retinal diseases (including neovascular AMD and diabetic macular oedema): biosimilar vs reference anti-VEGF injections showed no significant differences in visual acuity, retinal thickness or adverse events over 12-63.6 weeks.
Meta-analysisn = 25 studies
Pandya et al. EFFECTIVENESS AND SAFETY OF BIOSIMILAR ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR FOR RETINAL DISEASES: A Systematic Review and Meta-Analysis